K Pharma (TSE:4896) Change In Receivables : 円0 Mil (TTM As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is K Pharma Change In Receivables?

K Pharma's change in receivables for the quarter that ended in Mar. 2024 was 円0 Mil. It means K Pharma's Accounts Receivable stayed the same from Dec. 2023 to Mar. 2024 .

K Pharma's change in receivables for the fiscal year that ended in Dec. 2023 was 円0 Mil. It means K Pharma's Accounts Receivable stayed the same from Dec. 2022 to Dec. 2023 .

K Pharma's Accounts Receivable for the quarter that ended in Mar. 2024 was 円0 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. K Pharma's liquidation value for the three months ended in Mar. 2024 was 円2,838 Mil.

K Pharma Change In Receivables Historical Data

The historical data trend for K Pharma's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

K Pharma Change In Receivables Chart

K Pharma Annual Data

Trend

Dec21

Dec22

Dec23

Change In Receivables

K Pharma Quarterly Data
	Dec21	Dec22	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial			-	-	-	-	-

K Pharma Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was 円0 Mil.

K Pharma (TSE:4896) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

K Pharma's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, K Pharma's accounts receivable are only considered to be worth 75% of book value:

K Pharma's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	2934.171	-	100.737	+	0.75 * 0	+	0.5 * 9.364
=	2,838

K Pharma Change In Receivables Related Terms

Thank you for viewing the detailed overview of K Pharma's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

K Pharma (TSE:4896) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » K Pharma Inc (TSE:4896) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

7-7-7 Roppongi, Minato-ku, Tokyo, JPN, 106-0032

Website

https://en.kpharma.co.jp

K Pharma Inc is a company involved in Research, development, manufacturing, sales and marketing of pharmaceutical products and regenerative medicine products. It is involved in studying of iPs cells in regnerative medecine to treat neurological conditions such as cerebral infarction and SCI.

K Pharma (TSE:4896) Headlines

No Headlines